Protocol for Global Integration Method in children with ASD aged 6 to 12 years

Photo by Yoel Winkler / Unsplash

Frontiers in Medicine Published April 22, 2026 Medically reviewed April 25, 2026 DOI ↗ By Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

Key Takeaway

Note that this is a protocol with no results or safety data available for the Global Integration Method in ASD.

This study is a randomized controlled trial protocol focusing on children with autism spectrum disorder (ASD) aged 6 to 12 years who are classified as requiring level 1 or 2 support. The setting is not reported. The sample size is planned at 66 participants.

The intervention involves the Global Integration Method (Método de Integração Global - MIG) program. The comparator consists of conventional psychological intervention combined with conventional motor physiotherapy. The primary outcome measures fundamental motor skills and functional goal attainment. Secondary outcomes include balance, sociocommunicative skills, and motor performance.

Follow-up assessments are scheduled immediately post-intervention and three months after completion. Adverse events, serious adverse events, discontinuations, and tolerability are not reported in this protocol. Consequently, no main results or safety data can be summarized yet.

Limitations and funding or conflicts of interest are not reported. The practice relevance and certainty notes are not reported. Because this is a protocol, no causal conclusions or clinical recommendations regarding efficacy can be drawn.

Study Details

Study typeRct

EvidenceLevel 2

PublishedApr 2026

View Original Abstract ↓

IntroductionMotor impairments are highly prevalent in children with Autism Spectrum Disorder (ASD) and have been associated with reduced functional independence, participation, and sociocommunicative development. Despite the growing body of evidence supporting the relevance of motor functioning in ASD, motor-based interventions remain underrepresented in high-quality randomized clinical trials. The Global Integration Method (Método de Integração Global - MIG) is an intensive, interdisciplinary intervention grounded in the theories of predictive coding and embodied cognition, with emphasis on motor organization, proprioceptive stimulation, and generalization of functional skills in real-life contexts.ObjectiveThe aim of this study is to evaluate the effectiveness of the MIG program in improving fundamental motor skills and achieving functional goals, compared with conventional physiotherapy and psychological interventions, in children with ASD. Secondary objectives are to investigate the effects of MIG on balance, sociocommunicative skills, and motor performance.Methods and analysisThis is a three-arm randomized controlled trial with concealed allocation and blinded outcome assessors. Sixty-six children with ASD, aged 6 to 12 years, classified as requiring level 1 or 2 support, will be randomized into one of three groups: (I) MIG program, (II) conventional psychological intervention, and (III) conventional motor physiotherapy. Interventions will last five weeks. Assessments will be conducted at baseline, immediately post-intervention, and three months after completion. Primary outcomes include fundamental motor skills and functional goal attainment. Secondary outcomes include measures of balance, sociocommunicative skills, and motor performance. Data will be analyzed using linear mixed-effects models, following the intention-to-treat principle.Ethics and disseminationThe protocol was approved by the Research Ethics Committee of the Faculty of Medical Sciences of Minas Gerais, Brazil (Approval No. 7,456,658). Written informed consent will be obtained from parents or legal guardians, and assent will be sought from participating children when developmentally appropriate. Study findings will be disseminated through peer-reviewed publications, conference presentations, and reports to participating families and institutions.Clinical Trial RegistrationThis protocol was prospectively registered in the Brazilian Registry of Clinical Trials https://ensaiosclinicos.gov.br/rg/RBR-7r6n8zd, identifier U1111-1326-2272.